Infectious Disease Therapies Research and Innovation Act of 2020
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Jul 9, 2020)
Infectious Disease Therapies Research and Innovation Act of 2020
This bill exempts from the definition of passive activity, for purposes of the passive loss tax rules, any qualified medical research activity of a specified medical research small business pass-thru entity.
The bill defines specified medical research small business pass-thru entity as any domestic pass-thru entity if more than 80% of such entity's expenditures on research are paid or incurred in connection with qualified medical research activities and the gross receipts of such entity for the taxable year are less than $1 million.
What just happenedJul 9, 2020
Referred to the House Committee on Ways and Means.
Who’s behind it
- Introduced in HouseJul 9, 2020
- Jul 9, 2020IntroReferralH11100
Referred to the House Committee on Ways and Means.
Ways and Means Committee - Jul 9, 2020Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Jul 9, 2020IntroReferralIntro-H
Introduced in House
- Jul 9, 2020IntroReferral1000
Introduced in House